Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Successful production start of OXE300 in Poland

The first OXE300 has been assembled and shipped from PanLinks Polish site at the special economic zone of Tczew.The development of the production set up for the OXE300 advances according to plan, well in line with the previously communicated goal to start production of OXE300 in Tczew (Poland) under the first quarter this year. Assembly of the first three units has recently been finalized and are waiting to be shipped out. Two more units are expected to be finalized before this weeks end. OXE Marine AB (NASDAQ STO: OXE) (OTCQB: CMMCF) personnel are on site to align the production process

INVITATION TO PRESENTATION OF Q4-2020 FINANCIAL RESULTS

Date rectification: the release this morning referred the date for the earnings release on 17 February 2010, this should be 17 February 2021. Oslo, Norway (10 February 2021) — NattoPharma will release its fourth quarter financial results on Wednesday 17[th] February 2021 at approximately 07:00 CET. The report will be made available at www.nattopharma.com and at www.oslobors.no. The same day, starting at 10:00 am, the company will host a webcast with a presentation of the results followed by an online Q&A session. Please follow the below link to join the web-cast, https://channel.

Ework Group AB (publ) publishes Year-End Report, January – December 2020: Continued recovery in the fourth quarter

“We're proud to report a fourth quarter with continued recovery. Thanks to our employees' efforts, resolute cost reductions and our digital offering, we really succeeded in spite of the reduced demand in the year.” Extract from CEO Zoran Covics commentary to the Year-end reportFourth quarter 2020 compared to 2019 · Net sales were SEK 3,238 M (3,543). · EBIT was SEK 17.2 M (32.1). · Profit after financial items amounted to SEK 14.2 M (28.3). · Other operating income, and thus profit, was negatively impacted by SEK 4.3 M after a decision by the Board of Directors to repay

Sproud becomes first plant-based milk brand to receive SUGARWISE certification and appoints Registered Nutritionist, Charlotte Stirling-Reed, to advise on product developmen

[Sproud 4 ] Sproud (www.besproud.com), the Swedish startup behind a range of plant-based milk made from yellow split peas, has been certified by Sugarwise, the international certification authority for sugar claims.   The SUGARWISE certification, developed to help consumers make more informed and health-conscious decisions, marks a significant milestone for Sproud, as it becomes the first plant-based milk brand to receive it.   Sproud also announced today that it has appointed Registered Nutritionist, Charlotte Stirling-Reed, as its Nutrition Consultant to advise on the

AMENDMENT FOR ANNOUNCMENT NO. 34: NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 35 - 10 FEBRUARY 2021 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90/2020. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451

BONESUPPORT HOLDING AB (publ) – Full Year Report 2020 – invitation to conference call and webcast

Lund, Sweden, 10.00 am CET, 10 February 2021 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its Full Year Report 2020, on 17 February 2021 at 08.00 am CET. The Company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by Emil Billbäck, CEO and Håkan Johansson, CFO who will present the results and answer questions. The presentation will be held in English.   The dial-in numbers for the conference call are: SE: + 46 850558357UK: + 44 3333009270

Invitation to presentation of Eastnine’s Year-end Report 2020

Eastnine's Year-End Report will be published on Wednesday, February 17, 2021 at 7.00. The report is presented via Teams live the same day by Kestutis Sasnauskas, CEO of Eastnine, and Britt-Marie Nyman, CFO and Deputy CEO.Time for the Teams-broadcast Wednesday, February 17, 2021, 10.00 CET Please join the event a few minutes before the presentation begins. Presentation materials will be available at www.eastnine.com 15 minutes before the start of the webcast. Click here 

Ultrasonic device raises accuracy of re-lubrication

SKF’s Ultrasound Lubrication Checker fits to a grease gun, and helps technicians to re-lubricate bearings with high accuracy – avoiding both over- and under-lubrication.Gothenburg, Sweden, 10 February 2020: A unique ultrasonic device, which ‘listens’ to the sound of grease filling a bearing, makes the re-lubrication process more accurate and effective. By overcoming problems associated with over- or under-lubrication, the Ultrasound Lubrication Checker TLGU 10 from SKF can help to extend bearing lifetime. Re-lubrication is critical in prolonging the life of bearings and must be

Immunovia On Track For IMMray™ PanCan-d Sales Start In Q1 2021

LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) today provides an update on the status of the company’s activities and as previously reported (Webinar Dec 17, 2020 ), Immunovia will initiate sales start in Q1 2021 of the company’s first test, IMMray™ PanCan-d designed for early detection of pancreatic cancer. Since the last update, Immunovia’s R&D and production departments in Lund have been working at full speed to ensure the highest quality reagents and arrays are available for the final blind validation study of IMMray™

Asset purchases and zero interest rate providing support to the recovery and inflation

The Swedish economy has withstood the second wave of infection relatively well, supported by extensive economic policy measures. Vaccinations are now underway in many countries and despite continued uncertainty, the conditions for a rise in demand will be favourable when the spread of infection and restrictions are reduced. To facilitate the recovery and help inflation rise towards the target, monetary policy needs to remain expansionary. The Riksbank is therefore continuing to purchase assets within the envelope of SEK 700 billion. The repo rate is being left unchanged at zero per cent.

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 34 - 10 FEBRUARY 2021 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90/2020. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451

Use of electrical dryers significantly reduces CO\2\ footprint at Engebø

Nordic Mining has decided to use electrical dryers instead of gas fueled dryers in the mineral processing of rutile and garnet at Engebø. This will reduce the CO\2\ emissions with over 80%. Nordic Mining has in the process to update the definitive feasibility study (DFS) for Engebø been able to commercialize a concept for use of electrical dryers for drying of minerals in the production process. The concept uses proven technology that has been qualified for increased production volumes. Use of electrical dryers will reduce the CO\2\ emissions from the project and in effect make the

ExpreS2ion’s CEO in interview on achievements in 2020 and the company’s outlook for 2021

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) publishes an interview with the company’s CEO Bent Frandsen, in which he sums up the company’s achievements in 2021 and the outlook for the rest of 2021 and beyond. This includes discussing the status of the ABNCoV2 COVID-19 vaccine program and the recently in-licensed ES2B-C001 HER2 breast cancer vaccine project.The CEO interview is available via this link: https://mailchi.mp/expres2ionbio.com/february2021   Certified Adviser Svensk Kapitalmarknadsgranskning AB Telefon: +46 11 32 30 732 E-post: ca@skmg.se

Coor acquires R & K Service in Norway

Coor today signed an agreement regarding the acquisition of Norwegian company R & K Service AS, which delivers cleaning and restaurant services. R & K Service has 130 employees with annual sales of some SEK 80 M. The acquisition strengthens Coor’s offering in cleaning and restaurant services and increases Coor’s geographical coverage in the Stavanger region.The purchase consideration (on a cash and debt free basis) amounts to some SEK 65 M and corresponds to an EV/EBITA multiple of approximately 7x in relation to current EBITA, and approximately 5x when expected synergies have been realized

RLS GLOBAL AB (publ) YEAR-END REPORT 2020

OCTOBER 1[st]–DECEMBER 31[st] · Net sales amounted to KSEK 139 (KSEK 54) · Earnings before interest and taxes (EBIT) amounted to MSEK -7,2 (MSEK -8,9) · Earning per share before dilution at SEK -0,11 (SEK -0,15) · Cash flow from operating activities amounted to MSEK -7,0 (MSEK -5,7) · Liquid assets at the end of the period MSEK 18,9 (MSEK 41,7) · Equity ratio was 88 % (90 %)  JANUARY 1[st]–DECEMBER 31[st] · Net sales amounted to KSEK 2,043 (KSEK 1,023) · Earnings before interest and taxes (EBIT) amounted to MSEK -22,3 (MSEK -26,7) · Earning per share

Recipharm bolsters biologics offering

Global contract development and manufacturing organisation (CDMO), Recipharm, has successfully extended its manufacturing license to include immunology products, allowing them to cater for customers’ vaccine products at clinical and commercial scales, in both freeze-dried and liquid forms. The license, which applies to its facility in Wasserburg, Germany, also covers microbiological testing allowing Recipharm to insource bacterial endotoxin testing on its products, including testing diluent for one of the COVID-19 vaccines.  Kjell Johansson, President Manufacturing Services Europe

Axactor SE - Acceptances received under mandatory offer

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Reference is made to the mandatory offer dated 29 January 2021 (the "Mandatory Offer") to acquire all shares in Axactor SE (the "Company") at an offer price of NOK 8.00 per share, made by Geveran Trading Co. Limited, a company indirectly controlled by trusts established by Mr. John Fredriksen for the benefit of his immediate family ("Geveran").  On 9 February 2021,

Affibody and Inmagene announce IND Clearance for Izokibep (ABY-035) for the treatment of Ankylosing Spondylitis

Partners eye additional applications in autoimmune diseases during 2021  San Diego, U.S., Shanghai, China, and Solna, Sweden, February 10, 2021. Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced that the U.S. FDA has cleared izokibep (ABY-035) to proceed to Phase 2 clinical development in Ankylosing Spondylitis (AS), a subset of Axial Spondyloarthritis (axSpA). The partners are jointly developing izokibep to treat multiple autoimmune diseases, and Inmagene has taken the responsibility to manage the global clinical trials for axSpA.“Obtaining FDA IND

SimCorp A/S – New Share buyback program

Company Announcement no. 02/2021 SimCorp A/S (“SimCorp”) has today initiated a share buyback program for up to EUR 20.0m, to be executed during the period from 10 February 2021 to 31 July 2021. The buyback program is being launched in accordance with the authorization granted by the shareholders at the Annual General Meeting on 24 March 2020 to repurchase up to 10% of the SimCorp’s share capital in the period until the next annual general meeting. The buyback program will be structured and carried out in compliance with the provisions of Regulation No. 596/2014 of the European

Board of Directors’ Proposals to Raisio plc’s Annual General Meeting 2021

Raisio plc, Stock Exchange Release, 10 February 2021 Board of Directors’ Proposals to Raisio plc’s Annual General Meeting 2021 Raisio plc’s Annual General Meeting is planned to be held on 13 April 2021 at 2 p.m. (EET) in Raisio, Finland. The Annual General Meeting will be convened based on the temporary legislative act to limit the spread of Covid-19 pandemic (677/2020). Therefore, the shareholders and their proxy representatives will be able to participate in the Annual General Meeting and exercise the shareholders’ rights only by voting in advance and by submitting counterproposals

Rottneros announces price hike for SW BCTMP in South East Asia

Rottneros announces price hike of 75 USD/ton for all new SW BCTMP orders for South East Asian destinations effective from 10th of February 2021.The increase reflects that the overall pulp and SW BCTMP markets are in better balance today, following strong demand from the paper board and other paper segments as well as reduced inventories. Rottneros is a supplier of fibre for selected niche and speciality paper and board applications. Rottneros offers a wide selection of High Yield and Kraft Pulp (bleached and unbleached) made from sustainably managed Nordic soft wood forests.Kasper

INVITATION TO PRESENTATION OF Q4-2020 FINANCIAL RESULTS

Oslo, Norway (10 February 2021) — NattoPharma will release its fourth quarter financial results on Wednesday 17[th] February 2010 at approximately 07:00 CET. The report will be made available at www.nattopharma.com and at www.oslobors.no. The same day, starting at 10:00 am, the company will host a webcast with a presentation of the results followed by an online Q&A session. Please follow the below link to join the web-cast, https://channel.royalcast.com/landingpage/hegnarmedia/20210217_9/ The presentation and following Q&A session will be conducted in English and it will be

Klarna launches bank account in Germany

Berlin, 10th of February 2021 - Klarna, the leading global payment and shopping service, is launching consumer bank accounts in Germany, with the aim to provide them with further control of their finances. The launch marks a first for the company and will allow customers to easily track, categorize and analyze all of their everyday spending using the Klarna app. A Klarna bank account will come with a Visa debit card which can also be connected to both Google Pay and Apple Pay. The offering will exclusively be made available to a limited number of Klarna’s most loyal consumers to intensively

Inhalation Sciences’ PreciseInhale receives extended international Registered Trademark

(Stockholm, 10 February 2021) PreciseInhale[®], Inhalation Sciences’ flagship high-precision aerosol generator for preclinical respiratory research, has received an extended international Registered Trademark from the International Bureau of the World Intellectual Property Organization (WIPO). ISAB CEO Manoush Masarrat: “This will play an important role in protection of our trademark and driving the growth of PreciseInhale[®] in many strategic global markets.”The new trademark will last for ten years and designates PreciseInhale[®] as unique and protected not only in the European market –

There are no items matching the current filter
There are no more items matching the current filter
Back to top